NASDAQ:IMNM News 15 December 2025

Why Immunome stock is up today: IMNM jumps 7% as biotech firms up and JPM conference looms

Immunome shares rose 7.4% to $21.97 Friday after recent Phase 3 data showed its lead drug varegacestat cut disease progression or death by 84% in desmoid tumor patients. The company plans to file for FDA approval in Q2 2026. Immunome also granted stock options to three new hires and will present at the J.P. Morgan Healthcare Conference on Jan. 14.

9 January 2026

NASDAQ:IMNM·NASDAQ:SWTX·Stock Market·XETRA:MRK

Immunome (IMNM) stock drops 5% as biotech slips; investors look to Jan. 14 update

Immunome shares fell 5.3% to $19.72 in late trading Monday, underperforming biotech indexes and dropping below December’s $21.50 offering price. About 1.6 million shares changed hands by 3:54 p.m. EST. The company’s next update is expected at the J.P. Morgan Healthcare Conference on Jan. 14. No new company news has been released since December 16.

5 January 2026

NASDAQ:IMNM·Stock Market

Immunome (IMNM) Stock Surges After Positive Phase 3 Varegacestat Data: Latest News, Analyst Forecasts, and What Comes Next (Dec. 15, 2025)

December 15, 2025 — Immunome, Inc. (NASDAQ: IMNM) is having the kind of biotech day that traders circle in red ink: a major clinical trial win, a sharp move in the share price, and a fast-rising debate over what “best-in-class” might be worth if regulators agree. The catalyst is Immunome’s positive topline Phase 3 RINGSIDE results for varegacestat (formerly AL102) in progressing desmoid tumors—a rare, non-metastatic but often aggressive disease that can cause severe pain and disability. Reuters reported the news pushed the stock up 34.3% in premarket trading Monday. Reuters By mid-session, IMNM remained strongly higher. As of 14:46

15 December 2025

NASDAQ:IMNM

SK hynix stock price slips to 839,000 won as Korea tech selloff bites — what to watch next week

8 February 2026

SK hynix closed Friday down 0.36% at 839,000 won as the KOSPI slid 1.4%, snapping a six-week winning streak. Global DRAM shortages and rising AI demand are pushing memory prices higher, with Apple warning of sharp increases. SK hynix goes ex-dividend on Feb. 26. Seoul’s market reopens Monday, with traders eyeing tech sentiment and memory supply signals.

Micron stock pops 3% into the weekend as UBS calls memory shortage “deeper into 2027”

8 February 2026

Micron shares closed up 3.1% at $394.69 Friday after UBS raised its price target to $450, citing ongoing memory chip shortages. The stock traded between $372.87 and $396.65 on volume of 37.2 million shares. Micron executives are set to speak at a Wolfe Research conference Feb. 11.

ASML stock price jumps on AI-spending rebound — dividend dates and U.S. data ahead

8 February 2026

ASML shares closed up 3.84% in Amsterdam at 1,193.80 euros and rose 4.6% in New York to $1,413.01 on Friday. Chip stocks rebounded as investors bet on continued AI data center spending. ASML’s ex-dividend dates are Feb. 9 in Amsterdam and Feb. 10 in New York. U.S. jobs and inflation data next week may affect tech valuations.

Nvidia stock price jumps nearly 8% on AI spending signals — what to watch before Monday

8 February 2026

Nvidia shares jumped 7.9% to $185.41 Friday, leading chip stocks higher on renewed bets that AI data-center spending by Amazon and Alphabet will surge. The VanEck Semiconductor ETF climbed 5.4%. Investors await U.S. jobs and inflation data next week, then Nvidia’s earnings on Feb. 25.

NASDAQ:IMNM News 15 December 2025 - 9 January 2026

Why Immunome stock is up today: IMNM jumps 7% as biotech firms up and JPM conference looms

Immunome (IMNM) stock drops 5% as biotech slips; investors look to Jan. 14 update

Immunome (IMNM) Stock Surges After Positive Phase 3 Varegacestat Data: Latest News, Analyst Forecasts, and What Comes Next (Dec. 15, 2025)

Stock Market Today

SK hynix stock price slips to 839,000 won as Korea tech selloff bites — what to watch next week

Micron stock pops 3% into the weekend as UBS calls memory shortage “deeper into 2027”

ASML stock price jumps on AI-spending rebound — dividend dates and U.S. data ahead

Nvidia stock price jumps nearly 8% on AI spending signals — what to watch before Monday